A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins

Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 135-137

  Antoine, Daniel J ^a   Harris, Helena Erlandsson ^b   Andersson, Ulf ^b   Tracey, Kevin J ^c   Bianchi, Marco E ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DISULFIDE HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; REDUCED HIGH MOBILITY GROUP B1 PROTEIN; SULFONYL HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CYTOKINE RELEASE; DISULFIDE BOND; HISTONE MODIFICATION; HYDROGEN BOND; NOMENCLATURE; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE;

BINDING SITES; BIOLOGICAL MARKERS; CYSTEINE; HMGB1 PROTEIN; HUMANS; OXIDATION-REDUCTION; TERMINOLOGY AS TOPIC;

EID: 84898683559     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00022     Document Type: Article

References (8)

1. Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139-62.
2. Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519-28.
3. Yang H, et al. (2012). Redox modification of cysteine residues regulates the cytokine activity of HMGB1. Mol. Med. 18:250-9.
4. Kazama H, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspasedependent oxidation of high-mobility group box-1 protein. Immunity. 29:21-32.
5. Tang D, et al. (2010) Endogenous HMGB1 regulates autophagy. J. Cell. Biol. 190:881-92.
6. Dear JW, Antoine DJ. (2014) Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges. Expert. Rev. Clin. Pharmacol. 7:181-9.
7. Turner BM. (2005) Reading signals on the nucleosome with a new nomenclature for modified histones. Nat. Struct. Mol. Biol. 12:110-12.
8. Gould N, Doulias PT, Tenopoulou M, Raju K, Ischiropoulos H. (2013) Regulation of protein function and signaling by reversible cysteine S-nitrosylation. J. Biol. Chem. 288:26473-9.